Introduction
Glutamate activates three major types of ionotropic receptors in the central nervous system: ␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), kainate and N-methyl-D-aspartate (NMDA) receptors. In contrast to AMPA and kainate receptors, modulation of NMDA receptor function occurs at a number of sites that are distinct from the glutamate-binding site. One of these is the strychnine-insensitive glycine-binding site where glycine allosterically increases the probability of the open state of NMDA receptor channels.
to the glycine-binding site and can modulate NMDA receptor function. 1, 5, 6 NMDA receptor activation is thought to play an important role in the formation of neural networks during development and in synaptic plasticity, physical correlates of memory and learning. For example, pharmacological blockade of NMDA receptors or knockout of the NMDA receptor gene in hippocampal CA1 pyramidal neurons significantly disrupted some types of memory and learning in animals. [7] [8] [9] Likewise, ketamine significantly disturbed verbal memory in humans by inhibiting NMDA receptors in the hippocampal CA1 area. 10 The investigation of NMDA receptor function at experimental conditions known to be associated with impaired memory formation and learning in vivo may provide further insight into the role of NMDA receptors in these processes. Specifically, phenylketonuria (PKU), an autosomal recessive disorder marked by extremely high blood concentrations of the amino acid L-phenylalanine (Ͼ1200 M vs 55-60 M in healthy subjects), is characterized by severe neurological deficits such as mental retardation and postnatal brain damage. 11, 12 The neurological manifestations of phenylketonuric subjects develop rapidly within the first months of life. 11, [13] [14] [15] While it is well established that hyperphenylalaninemia is caused by mutations of the gene encoding phenylalanine hydroxylase, an enzyme that catalyzes the conversion of L-phenylalanine (LPhe) to L-tyrosine (L-Tyr), 12, 16, 17 the mechanism whereby hyperphenylalaninemia results in mental retardation is not understood. If hyperphenylalaninemia specifically impairs NMDA receptor function then, PKU as well as its associated animal models such as the genetic murine model of PKU (Pah enu2 ) 18, 19 can be used to study the role of NMDA receptors in learning and memory.
Therefore, to examine whether impairment of NMDA receptor function in the hippocampus could be involved in the development of mental retardation associated with PKU, we investigated the effect of LPhe on the NMDA-activated current (I NMDA ) in cultured hippocampal neurons from newborn rats.
Materials and methods

Cell preparation
Hippocampi were dissected from newborn rats and treated with 0.25% trypsin to dissociate cells, using the exact procedures that were employed for preparation of cortical cultures. 20 Dissociated cells were resuspended in Neurobasal Medium containing B-27 serumfree supplement (Invitrogen Life Technologies, Carlsbad, CA, USA), and were plated in poly-L-lysine coated 35-mm Nunc plastic tissue culture dishes (1.5 × 10 6 cells per dish per 2 ml media). Cells were cultured in an atmosphere of 5% CO 2 /95% air, and 50% of the media was replaced every 3 days. Neurons were used for electrophysiological recordings 7-20 days after plating.
Electrophysiological recordings
Electrophysiological recordings of I NMDA in cultured rat hippocampal neurons were made in the whole cell configuration of the patch-clamp technique 21 using an Axopatch 200B amplifier (Axon Instruments, Foster City, CA, USA). Patch microelectrodes were pulled from 1.5-mm borosilicate glass tubing using a two-stage vertical pipette puller (Narishige, East Meadow, NY, USA). When filled with recording solution, patch microelectrodes had a resistance of 3-5 M⍀. For rapid application of agonist-containing solutions to neurons, the SF-77B system (Warner Instrument Corp, Hamden, CT, USA) was used. Current data were digitized online using a DigiData 1200A analog-to-digital board and stored on the hard disc of an IBM compatible Pentium computer (GP7-600 MHz, Gateway Computer, Sioux City, ND, USA). Voltage-clamp experimental protocols and off-line data analysis were performed using the software program pCLAMP7 (Axon Instruments). The experiments were performed at room temperature (22-23°C).
In order to examine whether impairment of NMDA receptor function in the hippocampus can be potentially involved in the development of mental retardation associated with PKU, we investigated the effect of L-Phe on I NMDA in rat hippocampal neurons at conditions similar to those at which NMDA receptors are active in vivo. Therefore, experiments were performed at a V H of −30 mV and the extracellular solutions contained Mg
2+
. I NMDA was recorded in response to a 6-s period of NMDA application in the presence of glycine (0.1 M), unless stated otherwise.
Solution and drugs
The extracellular control solution contained (in mM): NaCl 140, KCl 4, CaCl 2 2, MgCl 2 1, CsCl 3, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 10, and glucose 11. The pH of the extracellular solution was adjusted to 7.4 using NaOH. Tetrodotoxin (TTX, 0.3-1 M) was added to the external solution to block voltage-gated Na 
General data analysis
Values are reported as mean ± SEM. Prior to parametric testing, the assumption of normality was validated using the Kolmogorov-Smirnov test with Lilliefor's correction (SSPS v10, SPSS, Inc, Chicago, IL, USA). Multiple comparisons among groups were analyzed using ANOVA (two-or one-way repeated measures with two or one-way replication where appropriate) followed by Student-Newman-Keuls testing. Single comparisons were analyzed using a 2-tailed Student's t-test. A P Ͻ 0.05 was considered significant.
Results
NMDA (100 M) activated a rapidly rising inward current (ie, I NMDA ) that decayed from a peak value of 796 ± 45 pA to a steady state value of 344 ± 25 pA (n = 56). High concentrations of L-Phe (Ն1 mM) significantly attenuated I NMDA (Figure 1a ). L-Phe (1 mM) decreased the peak and steady-state values of I NMDA to 549 ± 36 pA (67.9 ± 1.1% of control values) and 294 ± 21 pA (85.8 ± 1.1% of control values), respectively (n = 56, P Ͻ 0.001). L-Phe was found to inhibit the peak component of I NMDA in all neurons tested, whereas it did not significantly change the steady-state component of I NMDA in eight neurons of 56 studied. The effect of L-Phe on I NMDA was reversible upon washout of the drug from the extracellular solution.
In contrast to L-Phe, L-Tyr, the amino acid produced Figure 2 ). L-Phe (1 mM) decreased the peak components of I NMDA by 20.7 ± 3.4% and 32.1 ± 1.1% (n = 4, P Ͻ 0.01) at membrane potentials of +30 mV and −30 mV, respectively.
The attenuation of I NMDA caused by L-Phe was concentration-dependent with the threshold effect occurring at concentrations greater than 200 M (Figure 3a,b) . Analysis of the concentration-response curve for the effect of L-Phe on I NMDA using a non-linear logistic regression technique showed that the concentration of L-Phe required to cause half-maximal inhibition of I NMDA (IC 50 ) was 1.71 ± 0.24 mM, whereas the Hill coefficient was 0.94 ± 0.11 (ie, a value not significantly different from unity, P = 0.61). The concentration-response relationship for L-Phe to attenuate the steady-state component of I NMDA lies to the right of that to attenuate the peak component of I NMDA . The effect of L-Phe on I NMDA was reversible at all concentrations of L-Phe studied.
To determine whether the effect of L-Phe on I NMDA depends on the concentration of NMDA, I NMDA was measured at the same concentration of L-Phe (1 mM) and different concentrations of NMDA. An increase in In order to assess if L-Phe inhibits I NMDA by allosterically interacting with the glycine-binding site of the NMDA receptor, the effects of L-Phe on I NMDA were studied at a constant concentration of NMDA (100 M) in combination with a higher concentration of glycine (1 M vs 0.1 M). Increasing the concentration of glycine from 0.1 to 1 M significantly increased the amplitude of I NMDA . The peak and steady-state components of I NMDA in the presence of glycine (1 M) were 138.9 ± 7.8% (n = 7, P = 0.01) and 188.2 ± 8.6% (n = 7, P = 0.01), respectively, of those measured in the presence of glycine (0.1 M). The increase in the concentration of glycine significantly decreased the inhibitory effect of L-Phe on I NMDA , and markedly shifted the concentration-response relationship rightward (Figure 3d ). Similar to the effect of L-Phe on I NMDA in the presence of a lower concentration of glycine, L-Phe was more effective at inhibiting the I NMDA peak component than its steady-state component. At a glycine concentration of 1 M L-Phe (1 mM) decreased the peak and steadystate component of I NMDA to 88.9 ± 1.0% (P = 0.002) and 94.1 ± 1.0% (P = 0.038, n = 9) of control values, respectively. Likewise, a higher concentration of glycine increased the threshold concentration of L-Phe required to significantly inhibit I NMDA from 200 M to 1200 M. In these experiments, it was not possible to determine the IC 50 and Hill coefficient values from the L-Phe-I NMDA concentration-response relations because the inhibitory effect of L-Phe on I NMDA did not attain a plateau value, even at concentrations of L-Phe up to 30 mM.
To obtain additional evidence that L-Phe inhibits I NMDA by competing with glycine for the glycine-binding site on the NMDA receptor, the effect of L-Phe on I NMDA was studied in the presence of D-alanine. The amino acids alanine and serine bind to the glycinebinding site and potentiate the glutamate responses of NMDA receptors. The D-isomers of alanine and serine are 10 to 100-fold more potent than their L-isomers. 6 As expected, the addition of D-alanine (10 M) to the extracellular solution significantly increased the amplitude of I NMDA . D-alanine increased the peak and steadystate components of I NMDA to 119.1 ± 1.5 and 126.5 ± 4.9% of control value, respectively. In the presence of D-alanine, L-Phe (1 mM) had no significant effect on I NMDA . The peak and steady-state components of I NMDA were 116.9 ± 2.3 and 124.8 ± 5.5% (n = 4) of control value, respectively. However, L-Phe markedly inhibited I NMDA in the same neurons after washout of D-alanine. Representative records of I NMDA recorded from the same neuron in control, in the presence of LPhe (1 mM), and in the presence of D-alanine (10 M) with or without L-Phe (1 mM) are shown in Figure 4a .
If L-Phe inhibits I NMDA selectively by interacting with the glycine-binding site on the NMDA receptor, then other subtypes of glutamate receptors should be insensitive to this action of L-Phe because they lack glycinebinding sites. To test this hypothesis, we studied the effects of L-Phe on currents activated by: (1) the selecMolecular Psychiatry tive endogenous NMDA receptor agonist L-aspartate, 22 and the non-NMDA glutamate receptor agonist AMPA; and (2) glutamate in the absence and presence of the I NMDA blocker MK-801. [23] [24] [25] L-aspartate (100-1000 M) activated an inward current (I L-Asp ) similar to that activated by NMDA (Figure 4b, A) . At equal concentrations of agonist, the amplitude of I L-Asp was typically greater than that of I NMDA . L-Phe inhibited L-aspartate-and NMDA-activated currents to a similar extent. Peak components of I L-Asp and I NMDA , measured in the presence of L-Phe (2.5 mM), were 44.5 ± 2.5% (n = 11) and 44.1 ± 2.5% (n = 7) of control values, respectively (P = 0.92). Likewise, L-Phe (2.5 mM) decreased the steady-state components of I L-Asp and I NMDA to 56.7 ± 5.1% (n = 11) and 54.9 ± 2.3% (n = 7) of control values, respectively (P = 0.80). In contrast, L-Phe (2.5 mM) failed to attenuate significantly the current activated by AMPA in neurons in which the effects of L-Phe on I NMDA and I L-Asp were studied (Figure 4b, A) . At the same time, L-Phe attenuated the current activated by L-glutamate (300 M) (Figure 4b, B) . The peak component of the L-glutamate-activated current (I L-Glu ) was decreased to 61.1 ± 4.4% in the presence of L-Phe (2.5 mM). Despite a smaller relative inhibition of I L-Glu , in comparison with that of I L-Asp , the absolute values of the L-Phe-inhibited currents were similar. Specifically, the peak components of I L-Glu and I L-Asp were equally attenuated by 614 ± 52 pA (n = 5) and 632 ± 110 pA (n = 5, P = 0.85) from control values of 1678 ± 118 pA (n = 5) and 1122 ± 110 pA (n = 7), respectively. In addition, L-Phe did not significantly affect residual I L-Glu , after exposure of neurons to the NMDA receptor channel blocker MK-801 (5 M) (Figure 4b, B) .
To determine whether concentrations of L-Phe and L-Tyr observed either in healthy subjects or in phenylketonuric patients can interact to modulate NMDA receptor function, I NMDA was measured using two different experimental paradigms: (1) L-Phe 50 M and LTyr 100 M (to simulate healthy subjects); and (2) LPhe 1000 M and L-Tyr 100 M (to simulate hyperphenylalaninemia). The co-application of L-Phe (50 M) and L-Tyr (100 M) did not significantly change the amplitude of I NMDA relative to that measured in the absence of L-Phe and L-Tyr. Representative records of I NMDA recorded from the same neuron in control and in the presence L-Tyr (100 M) with either 50 or 1000 M of L-Phe are shown in Figure 4c . The amplitudes of the peak and steady-state components of I NMDA in the presence of L-Phe (50 M) and L-Tyr (100 M) were 99.9 ± 1.9 and 108.9 ± 1.9% of control values (measured before application of amino acids), respectively. In contrast, the co-application of L-Tyr (100 M) and the high concentration of L-Phe (1000 M) reduced peak and steady-state components of I NMDA to 70.0 ± 2.70 and 79.3 ± 2.3% of control values, respectively. A similar degree of inhibition of I NMDA was caused by L-Phe (1000 M) alone (69.4 ± 3.0 and 77.7 ± 2.1%, peak and steady-state values of control, respectively, n = 5). These results indicate that the inhibitory effect of high concentrations of L-Phe on I NMDA is not dependent upon the presence of physiological concentrations of L-Tyr in the extracellular solution.
Discussion
This is the first study to report that elevated concentrations of L-Phe, similar to those observed in the blood of phenylketonuric patients, can specifically and reversibly antagonize NMDA receptor current in rat cultured hippocampal neurons by competing for the glycinebinding site of the NMDA receptor. Because NMDA receptors are thought to play an important role in the mechanisms of synaptic plasticity and synapse formation that underlie memory, learning and formation of neural networks during development, 7-10 these results may not only help explain the neurologic manifestations of PKU, [11] [12] [13] [14] [15] but also suggest novel approaches to the study of NMDA receptor function.
Specific effect of L-Phe on I NMDA
High concentrations of L-Phe were found to specifically antagonize I NMDA in rat cultured hippocampal neurons. Consistent with a selective effect on I NMDA , L-Phe did not change the ionic current activated by AMPA, a non-NMDA receptor agonist of glutamate receptors. Likewise, L-Phe had no effect on the current activated by glutamate in the presence of the specific blocker of NMDA receptor channels MK 801. Conversely, in the absence of MK 801, L-Phe caused a similar attenuation of currents (on the basis of absolute values) activated by glutamate, NMDA or the specific NMDA receptor agonist L-aspartate.
The present data demonstrate that at normal blood concentrations, neither L-Phe nor L-Tyr, an aromatic amino acid synthesized from L-Phe by the enzyme phenylalanine hydroxylase, modulate I NMDA activity in rat hippocampal neurons. Furthermore, the inhibitory effect of high concentrations of L-Phe does not depend on the presence or absence of L-Tyr in the extracellular solution. L-Tyr did not significantly affect I NMDA , even at high concentrations. It should be noted that use of high concentrations of L-Tyr (1 mM) has only theoretical value, because the blood concentration of L-Tyr never exceeds 0.1 mM, either in healthy subjects or in patients with PKU. 26 Taken together these results suggest that L-Phe exerts its inhibitory action selectively on the NMDA subtype of ionotropic glutamate receptors.
L-Phe attenuates I NMDA by competing for the glycinebinding site NMDA receptors are unique among glutamate receptors because two co-agonists, L-glutamate and glycine, are required for their activation. Each agonist has a unique binding site within the NMDA receptor complex. Specifically, the binding sites for L-glutamate and glycine are located on two different subunits of the rat NMDA receptor, designated subunits 1 and 2, respectively. 27 Glycine significantly increases the probability of NMDA receptor channel opening caused by NMDA receptor agonists without significantly altering the mean open time or single channel conductance. 2, 3, 5, 28 At the same time, glycine does not influence the affinity of NMDA for the NMDA receptors. 29 Other amino
Molecular Psychiatry acids such as alanine and serine can also regulate NMDA receptor function by interacting with the glycine-binding site. 6 The results of this study provide evidence that L-Phe inhibits I NMDA by interacting with the glycine-but not the glutamate-binding site. This suggestion is supported by the finding that changes in the concentration of NMDA (from 100 M to 1000 M) did not alter the degree of L-Phe-induced inhibition of I NMDA , indicating a non-competitive nature of the L-Phe-NMDA receptor interaction. These results are in agreement with those of a prior study that found L-Phe (1 mM) neither affected NMDA-sensitive nor NMDA-insensitive L-[
3 H]-glutamate binding in rat brain synaptic membranes. 30 On the other hand, a 10-fold increase in the concentration of L-glycine significantly shifted the concentrationresponse curve for the effect of L-Phe on I NMDA rightward. This finding suggests that the glycine-binding site on the NMDA receptor is a possible target for the inhibitory action of L-Phe. In line with this assertion, D-alanine, an agonist of the glycine-binding site, significantly diminished (or prevented) the inhibitory effect of L-Phe on I NMDA . The fact that L-Phe selectively antagonized NMDA receptor function but did not influence other glutamate receptor subtypes provides additional indirect evidence that L-Phe is inhibiting I NMDA by interacting with the glycine-binding site.
Interaction of L-Phe with the glycine-binding site may explain the rightward shift of the inhibition caused by L-Phe of steady-state I NMDA compared to inhibition of peak I NMDA . It has been established that the affinity of the glycine-binding site to glycine is decreased following activation of the NMDA-receptor complex.
2,31 Because L-Phe also binds to the glycinebinding site of the NMDA receptor, it is possible that the affinity of the glycine-binding site for L-Phe may also decrease upon activation of I NMDA . Consequently, a higher concentration of L-Phe will be required to produce the same degree of inhibition of the steady-state component of I NMDA in comparison to the concentration of L-Phe required to diminish the peak component of I NMDA .
Because L-Phe likely acts at the glycine-binding site, the question of the effective concentration of glycine at NMDA receptors has critical importance for a possible pathophysiological role of L-Phe-impaired NMDA receptor function in the setting of PKU. The dissociation constant of glycine binding to NMDA receptors in cultured neurons and for most recombinant NMDA receptors varies from 100 to 300 nM. 2, 15, 28 The concentration of glycine in extracellular and cerebrospinal fluid is in the micromolar range (from 1 to 10 M), 32 which is sufficient to saturate the glycinebinding site on the NMDA receptor. If the concentration of glycine near NMDA receptors is sufficient to saturate the glycine-binding site, then L-Phe, at concentrations typically observed in patients with PKU, should have a minimal effect on NMDA receptor function in vivo (see Figure 4) . However, recent data indicate that the actual concentration of glycine near the NMDA receptor is markedly reduced by an active gly-cine transporter. 33, 34 For example, glycine-transporter expressed in Xenopus oocytes reduced the glycine concentration near the membrane to levels below 1 M when the bath glycine concentration was 10 M. 35 Likewise, whole-cell patch-clamp experiments from pyramidal neurons in hippocampal slices from 8 to 12 week-old rats demonstrated that a glycine transporter type 1 antagonist selectively increased the amplitude of the NMDA component of a glutamatergic excitatory postsynaptic current. 34 Glycine transport inhibition increased NMDA receptor function even during superfusion with medium containing 10 M glycine. 34 The additive effects of exogenous glycine and the glycine transporter type 1 antagonist provide evidence that the glycine binding site on the NMDA receptor is not saturated under physiological conditions. Therefore, the interaction of L-Phe with the glycine-binding site may attenuate NMDA receptor function during PKU.
Implications of I NMDA regulation by L-Phe
The finding that L-Phe, at concentrations observed during PKU, specifically inhibits NMDA receptor function may have important physiological and pathophysiological implications. Both PKU as well as its associated animal models are characterized by the development of severe cognitive impairments such as a learning deficit. 36, 37 The mechanism(s) whereby hyperphenylalaninemia produces these acquired mental defects is not known. The results presented above, namely the inhibition of I NMDA caused by high concentrations of L-Phe, may provide a cellular mechanism whereby hyperphenylalaninemia contributes to the development of mental retardation during PKU. In support of this contention, it is interesting to note that concentrations of L-Phe (0.4-0.7 mM), which are associated with a lower risk of brain damage during hyperphenylalaninemia, 38 only slightly attenuated I NMDA . If our hypothesis that impaired NMDA receptor contributes to the development of mental retardation in patients with PKU is correct, it may promote the development of specific therapeutic strategies (ie, use of glycine-binding site agonists or glycine transporter antagonists) aimed at mitigating PKU-related cognitive problems. Furthermore, demonstration of a specific role of NMDA receptor dysfunction as a contributor to deficits of memory formation and learning associated with PKU together with the availability of PKU animal models, 36,37 may provide a new approach to study and understand the basic molecular mechanisms of learning and memory under normal conditions.
In conclusion we found that in rat cultured hippocampal neurons L-Phe at concentrations observed in PKU patients specifically and reversibly attenuated NMDA receptor current by competing for the glycinebinding site. These results may have significant impact on understanding of the molecular mechanisms of mental retardation during PKU specifically and the molecular mechanisms of memory formation and learning in general.
